Schmidt, Charles <br/><br/>
The benefits of immunotherapy combinations.  [electronic resource] 

 -  Nature  12 2017 
 - S67-S69 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1476-4687 
<br/><br/><label>Standard No.: </label>10.1038/d41586-017-08702-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--immunology<br/>Antigens, Neoplasm--immunology<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>B7-H1 Antigen--antagonists & inhibitors<br/>Biomarkers, Tumor<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Cancer Vaccines--immunology<br/>Cell Cycle Checkpoints--drug effects<br/>Clinical Trials as Topic<br/>Combined Modality Therapy--adverse effects<br/>Drug Costs<br/>Humans<br/>Immunotherapy--economics<br/>Indoleamine-Pyrrole 2,3,-Dioxygenase--antagonists & inhibitors<br/>Ipilimumab--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Melanoma--drug therapy<br/>Nivolumab<br/>Oncolytic Virotherapy<br/>Patient Selection<br/>Precision Medicine<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Survival Analysis<br/>T-Lymphocytes--drug effects<br/>Tryptophan--analogs & derivatives<br/>Tumor Escape--drug effects